Biggest News Aggregation in the World

Page 4 - Michael Strapazon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Michael Strapazon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Michael Strapazon Today - Breaking & Trending Today

NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS - Press Release

Published: August 29, 2022

Earlier Treatment With Repatha Resulted in a Lower Incidence of Major CV Events, Including CV Death80% of Patients Achieved Guideline Directed LDL-C L

Source: wiredprnews.com

AMGEN FOUNDATION MORE THAN DOUBLES COMMITMENT TO LABXCHANGE, FREE VIRTUAL SCIENCE EDUCATION PLATFORM

Published: June 20, 2022

Founding and Lead Sponsor in Collaboration with the Vice Provost of Advances in Learning at Harvard UniversityTHOUSAND OAKS, Calif., June 20, 2022...

Source: businessinsider.com

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a)

Published: May 31, 2022

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive topline data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG...

Source: prnewswire.com

AMGEN AND LANCE BASS PARTNER TO ENCOURAGE PEOPLE TO DO A 'DOUBLE TAKE' TO RECOGNIZE THE EARLY SIGNS OF PSORIATIC ARTHRITIS

Published: May 12, 2022

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Source: apnews.com

AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB)

Published: April 27, 2022

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced top-line results from two Repatha® (evolocumab) open label extension (OLE) studies to the Phase 3 FOURIER...